A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

Journal:

The New England Journal of Medicine

Published:

2025-10-16

DOI:

10.1056/nejmoa2414719

Affiliations:

21

Authors:

22

Go to article

Institutions	Authors	Share
RemeGen, Ltd., China	2.500000	0.11
State Key Laboratory of Complex Severe and Rare Diseases, China	2.000000	0.09
The General Hospital, TMU, China	1.000000	0.05
First Hospital Affiliated to Baotou Medical College, IMUST, China	1.000000	0.05
Zhuzhou Hospital, China	1.000000	0.05
Pingxiang People's Hospital, China	1.000000	0.05
Affiliated Hospital of Guilin Medical University, China	1.000000	0.05
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	1.000000	0.05
Changhai Hospital, SMMU, China	1.000000	0.05
Affiliated Hospital of SDMPU, China	1.000000	0.05
The Second Affiliated Hospital, GMU, China	1.000000	0.05
Second Xiangya Hospital, CSU, China	1.000000	0.05
Jining First People's Hospital, China	1.000000	0.05
RemeGen - USA, United States of America (USA)	1.000000	0.05
Amsterdam Rheumatology and Immunology Center (ARC), Netherlands	1.000000	0.05
Shengjing Hospital of China Medical University, China	1.000000	0.05
Beijing Hospital, China	1.000000	0.05
Renji Hospital, SJTU, China	1.000000	0.05
Oklahoma Medical Research Foundation (OMRF), United States of America (USA)	0.500000	0.02
OU Health Sciences Center (OUHSC), United States of America (USA)	0.500000	0.02
Tongji University, China	0.500000	0.02

Interested in Clinical Sciences?